VERA Valuation

Vera Therapeutics Inc

Add to Watchlist

Advanced Chart

21.810

-0.07(-0.320%)1D

Overview
Forecast
Valuation
Earnings

VERA Relative Valuation

VERA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VERA is overvalued; if below, it's undervalued.

Historical Valuation

Vera Therapeutics Inc (VERA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -8.06. The fair price of Vera Therapeutics Inc (VERA) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：21.81

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

2.60

P/B

Median3y

5.65

Median5y

5.26

-11.21

FCF Yield

Median3y

-11.04

Median5y

-10.33

Competitors Valuation Multiple

The average P/S ratio for VERA's competitors is 76.45, providing a benchmark for relative valuation. Vera Therapeutics Inc Corp (VERA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

VERA.O

Vera Therapeutics Inc

Loss

Average P/S: 76.45

1.39B